PH vs TT vs EMR
161 measures in 16 categories, one definition each, computed from filings and market data.
PH66.9
Parker-Hannifin Corporation
Industrials · Industrial - Machinery
$963.34 +0.17%$121.5B mkt cap
Score DNA
TT66.5
Trane Technologies plc
Industrials · Industrial - Machinery
$458.89 +0.33%$101.0B mkt cap
Score DNA
EMR63.4
Emerson Electric Co.
Industrials · Industrial - Machinery
$161.47 −0.43%$90.1B mkt cap
Score DNA
Price, rebased to 100 three years ago
PH TT EMR · weekly adjusted closesSmart money 8Valuation 16Profitability (TTM) 12Returns on capital 11Growth 17Margin history & stability 7Liquidity (latest quarter) 7Leverage & solvency (latest quarter) 13Efficiency 11Cash flow & earnings quality 7Dividends & buybacks 9Scores & forensic checks 15Per share 7Size (TTM) 8Price performance 9Technicals 4
● marks the highest or lowest value where that direction is plainly stronger (margins, returns, coverage, leverage); multiples and yields are left unmarked. Bars show each stock's percentile within its own industry. n/a: the measure does not apply to lenders and insurers.
Smart money
8 measures| Measure | PH | TT | EMR |
|---|---|---|---|
| Insider open-market buys, 180d | 0 | 0 | 0 |
| Insider $ bought, 180d | — | — | — |
| Congress purchases, 180d | 5 | 2 | 1 |
| Last Congress purchase | 2026-05-15 | 2026-08-10 | 2026-09-25 |
| 13F net change in holders | +51 | — | +89 |
| ETFs adding shares, 30d | 1,085 | 1,355 | 1,096 |
| ETFs trimming, 30d | 882 | 1,135 | 927 |
| Net ETF funds, 30d | +203 | +220 | +169 |
Valuation
16 measures| Measure | PH | TT | EMR |
|---|---|---|---|
| P/E (TTM) | 33.3x
67th
|
34.2x
70th
|
35.0x
72nd
|
| PEG (P/E ÷ 3-yr EPS CAGR) | 1.56
48th
|
1.95
55th
|
— |
| Price / sales | 5.7x
93rd
|
4.5x
82nd
|
4.8x
87th
|
| Price / book | 7.9x
87th
|
11.7x
92nd
|
4.4x
67th
|
| Price / tangible book | — | — | — |
| Price / free cash flow | 31.1x
79th
|
28.3x
75th
|
26.0x
64th
|
| Price / operating cash flow | 27.8x
86th
|
25.9x
81st
|
23.0x
72nd
|
| Enterprise value | $129.5B
98th
|
$104.3B
97th
|
$101.7B
95th
|
| EV / sales | 6.0x
97th
|
4.7x
82nd
|
5.5x
90th
|
| EV / EBITDA | 21.9x
82nd
|
24.0x
88th
|
19.1x
68th
|
| EV / EBIT | 26.1x
72nd
|
26.4x
74th
|
26.5x
78th
|
| EV / free cash flow | 33.2x
75th
|
29.2x
59th
|
29.4x
61st
|
| Earnings yield | 3.0%
41st
|
2.9%
38th
|
2.9%
36th
|
| FCF yield | 3.2%
28th
|
3.5%
31st
|
3.8%
41st
|
| Operating cash flow yield | 3.6%
18th
|
3.9%
23rd
|
4.3%
31st
|
| Graham number (per share) | $278.23
100th
|
$107.64
83rd
|
$61.26
63rd
|
Profitability (TTM)
12 measures| Measure | PH | TT | EMR |
|---|---|---|---|
| Gross margin | 37.7%
52nd
|
35.4%
46th
|
53.2%
97th
|
| EBITDA margin | 27.4%
93rd
|
19.5%
56th
|
28.5%
95th
|
| Operating margin | 21.6%
90th
|
17.9%
74th
|
20.1%
85th
|
| EBIT margin | 23.1%
95th
|
17.8%
69th
|
20.6%
89th
|
| Net margin | 17.0%
93rd
|
13.3%
74th
|
13.8%
79th
|
| NOPAT margin | 17.2%
93rd
|
14.5%
77th
|
15.8%
82nd
|
| FCF margin | 18.2%
89th
|
16.1%
74th
|
18.6%
90th
|
| Operating cash flow margin | 20.3%
89th
|
17.6%
72nd
|
21.0%
90th
|
| R&D / revenue | 0.0%
0th
|
0.0%
0th
|
0.0%
0th
|
| SG&A / revenue | 16.1%
38th
|
17.4%
46th
|
28.1%
93rd
|
| Stock comp / revenue | 1.5%
92nd
|
0.4%
23rd
|
1.3%
85th
|
| Effective tax rate | 20.0%
30th
|
19.0%
27th
|
21.4%
52nd
|
Returns on capital
11 measures| Measure | PH | TT | EMR |
|---|---|---|---|
| ROE (on average equity) | 25.1%
85th
|
35.8%
93rd
|
12.8%
51st
|
| ROA | 12.1%
82nd
|
13.1%
87th
|
6.1%
49th
|
| ROIC | 15.8%
74th
|
27.0%
92nd
|
9.2%
44th
|
| ROCE | 20.0%
84th
|
25.4%
92nd
|
12.2%
56th
|
| Return on tangible assets | 16.4%
84th
|
17.6%
87th
|
9.0%
51st
|
| Cash ROIC (OCF / invested capital) | 18.6%
72nd
|
32.6%
95th
|
12.2%
47th
|
| Gross profitability (GP / assets) | 26.2%
61st
|
32.9%
79th
|
23.5%
46th
|
| ROIC, 3-yr average | 13.6%
72nd
|
21.9%
91st
|
6.9%
30th
|
| ROIC, 5-yr average | 13.7%
64th
|
21.9%
94th
|
18.8%
81st
|
| ROE, 5-yr average | 21.6%
81st
|
32.0%
96th
|
25.9%
93rd
|
| Incremental ROIC | 146.5%
85th
|
112.5%
83rd
|
-154.4%
12th
|
Growth
17 measures| Measure | PH | TT | EMR |
|---|---|---|---|
| Revenue growth (TTM YoY) | 8.3%
58th
|
7.0%
48th
|
4.8%
40th
|
| Revenue growth (QoQ) | 4.9%
25th
|
27.9%
93rd
|
6.8%
38th
|
| Revenue CAGR, 3 yr | 4.1%
53rd
|
9.7%
76th
|
4.3%
59th
|
| Revenue CAGR, 5 yr | 8.4%
63rd
|
10.4%
75th
|
0.9%
4th
|
| Gross profit CAGR, 3 yr | 7.7%
53rd
|
13.5%
81st
|
8.6%
63rd
|
| Operating income CAGR, 3 yr | 12.9%
69th
|
14.4%
73rd
|
7.3%
53rd
|
| Net income growth (TTM YoY) | 3.3%
57th
|
3.3%
55th
|
-2.8%
49th
|
| Net income CAGR, 3 yr | 20.5%
82nd
|
16.2%
76th
|
-42.0%
2nd
|
| EPS growth (TTM YoY) | 4.3%
57th
|
4.5%
59th
|
-2.2%
49th
|
| EPS CAGR, 3 yr | 21.3%
82nd
|
17.5%
76th
|
-41.6%
2nd
|
| EPS CAGR, 5 yr | 16.6%
76th
|
19.1%
87th
|
3.3%
26th
|
| FCF growth (TTM YoY) | 16.9%
62nd
|
27.0%
69th
|
26.2%
67th
|
| FCF CAGR, 3 yr | 14.5%
49th
|
32.9%
79th
|
18.0%
62nd
|
| Operating cash flow CAGR, 3 yr | 13.6%
51st
|
29.3%
81st
|
16.1%
58th
|
| Book value CAGR, 3 yr | 15.0%
77th
|
12.5%
64th
|
0.6%
11th
|
| Dividend CAGR, 3 yr | 24.2%
98th
|
4.6%
84th
|
1.8%
44th
|
| Sustainable growth rate | 14.0%
80th
|
25.1%
91st
|
6.7%
33rd
|
Margin history & stability
7 measures| Measure | PH | TT | EMR |
|---|---|---|---|
| Gross margin, 3-yr average | 36.8%
55th
|
35.4%
48th
|
52.0%
97th
|
| Operating margin, 3-yr average | 20.6%
92nd
|
17.8%
77th
|
18.2%
82nd
|
| Net margin, 3-yr average | 16.3%
93rd
|
13.1%
78th
|
13.0%
75th
|
| FCF margin, 3-yr average | 16.7%
87th
|
14.3%
80th
|
13.7%
73rd
|
| Revenue stability (0-1) | 0.89
68th
|
1.00
100th
|
0.16
7th
|
| Earnings stability (0-1) | 0.88
93rd
|
0.97
100th
|
0.02
12th
|
| Margin stability (0-1) | 0.88
18th
|
0.94
57th
|
0.90
25th
|
Liquidity (latest quarter)
7 measures| Measure | PH | TT | EMR |
|---|---|---|---|
| Cash & short-term investments | $501.0M
72nd
|
$1.3B
89th
|
$2.2B
95th
|
| Net cash (− = net debt) | −$8.0B
7th
|
−$3.3B
15th
|
−$11.6B
0th
|
| Working capital | $1.6B
89th
|
$615.9M
52nd
|
−$1.1B
3rd
|
| Current ratio | 1.26
15th
|
1.07
7th
|
0.90
3rd
|
| Quick ratio | 0.74
10th
|
0.76
16th
|
0.66
3rd
|
| Cash ratio (cash + ST investments / current liabilities) | 0.08
7th
|
0.16
26th
|
0.20
34th
|
| Defensive interval (days) | 418 days
34th
|
523 days
61st
|
310 days
16th
|
Leverage & solvency (latest quarter)
13 measures| Measure | PH | TT | EMR |
|---|---|---|---|
| Total debt | $8.5B
92nd
|
$4.6B
85th
|
$13.8B
98th
|
| Debt / equity | 0.55
50th
|
0.53
47th
|
0.68
65th
|
| Net debt / equity | 0.52
67th
|
0.38
48th
|
0.57
70th
|
| Debt / assets | 27.6%
54th
|
19.3%
26th
|
32.7%
70th
|
| Debt / capital | 35.6%
50th
|
34.8%
47th
|
40.4%
65th
|
| Debt / EBITDA | 1.44
29th
|
1.06
16th
|
2.60
64th
|
| Net debt / EBITDA | 1.36
39th
|
0.76
29th
|
2.19
71st
|
| Interest coverage (EBIT / interest) | 12.4x
70th
|
18.0x
84th
|
6.9x
46th
|
| Cash interest coverage | 10.9x
66th
|
17.7x
86th
|
7.1x
41st
|
| Debt payback (years of OCF) | 2.0 yrs
31st
|
1.2 yrs
19th
|
3.5 yrs
62nd
|
| Liabilities / assets | 50.1%
48th
|
63.9%
79th
|
51.7%
52nd
|
| IS credit model rating | AA- | AA+ | A- |
| Implied credit spread (bps) | 100
21st
|
65
5th
|
175
66th
|
Efficiency
11 measures| Measure | PH | TT | EMR |
|---|---|---|---|
| Asset turnover | 0.71
44th
|
0.99
70th
|
0.44
8th
|
| Fixed asset turnover | 7.12
69th
|
9.28
87th
|
6.51
59th
|
| Inventory turnover | 4.5
74th
|
5.8
92nd
|
3.6
48th
|
| Receivables turnover | 6.9
75th
|
5.3
30th
|
6.2
56th
|
| Days sales outstanding | 53 days
25th
|
68 days
70th
|
58 days
44th
|
| Days inventory outstanding | 82 days
26th
|
63 days
8th
|
100 days
52nd
|
| Days payables outstanding | 62 days
70th
|
70 days
82nd
|
60 days
64th
|
| Cash conversion cycle (days) | 72 days
10th
|
62 days
8th
|
98 days
34th
|
| Capex / revenue | 2.1%
48th
|
1.5%
7th
|
2.4%
53rd
|
| Capex / depreciation | 0.49
30th
|
0.84
67th
|
0.30
7th
|
| Operating expense ratio | 15.2%
23rd
|
16.3%
28th
|
33.9%
95th
|
Cash flow & earnings quality
7 measures| Measure | PH | TT | EMR |
|---|---|---|---|
| Operating cash flow / net income | 1.20
25th
|
1.32
38th
|
1.52
60th
|
| FCF / net income | 1.07
33rd
|
1.21
49th
|
1.34
67th
|
| FCF / operating cash flow | 89.5%
75th
|
91.5%
89th
|
88.4%
74th
|
| Capex / operating cash flow | 10.5%
25th
|
8.5%
11th
|
11.6%
26th
|
| Accruals ratio | -2.4%
66th
|
-4.2%
36th
|
-3.2%
54th
|
| Sloan accruals ratio | -1.6%
49th
|
-2.1%
38th
|
-2.2%
36th
|
| Earnings quality score (0-1) | 1.00
25th
|
1.00
25th
|
1.00
25th
|
Scores & forensic checks
15 measures| Measure | PH | TT | EMR |
|---|---|---|---|
| IS score | 67
80th
|
66
79th
|
63
70th
|
| IS profitability | 73
92nd
|
67
84th
|
57
67th
|
| IS growth | 50
55th
|
50
57th
|
41
37th
|
| IS value | 38
20th
|
34
11th
|
46
41st
|
| IS momentum | 75
55th
|
76
60th
|
71
48th
|
| IS risk (safety) | 100
48th
|
100
48th
|
100
48th
|
| IS quality | 87
95th
|
79
80th
|
80
82nd
|
| IS balance sheet | 62
46th
|
65
54th
|
54
31st
|
| IS earnings quality | 78
82nd
|
72
51st
|
77
79th
|
| IS cash flow | 69
72nd
|
76
85th
|
73
84th
|
| Piotroski F-score (0-9) | 9
92nd
|
6
36th
|
8
74th
|
| Altman Z-score | 7.2
89th
|
6.4
84th
|
4.3
49th
|
| Beneish M-score | −2.57
42nd
|
−2.56
47th
|
−2.61
30th
|
| Ohlson O-score | −8.95
18th
|
−7.93
52nd
|
−8.50
31st
|
| IS credit score | 85
72nd
|
90
92nd
|
67
33rd
|
Size (TTM)
8 measures| Measure | PH | TT | EMR |
|---|---|---|---|
| Market cap | $121.5B
98th
|
$101.0B
97th
|
$90.1B
95th
|
| Revenue | $21.5B
92nd
|
$22.2B
95th
|
$18.6B
90th
|
| EBITDA | $5.9B
98th
|
$4.3B
92nd
|
$5.3B
97th
|
| Net income | $3.6B
98th
|
$2.9B
95th
|
$2.6B
92nd
|
| Free cash flow | $3.9B
98th
|
$3.6B
97th
|
$3.5B
95th
|
| Total assets | $30.9B
92nd
|
$23.9B
90th
|
$42.2B
97th
|
| Shareholders' equity | $15.4B
97th
|
$8.6B
87th
|
$20.4B
100th
|
| Employees | 59,850
93rd
|
44,000
90th
|
71,000
97th
|
Price performance
9 measures| Measure | PH | TT | EMR |
|---|---|---|---|
| 1 day | +0.2% | +0.3% | −0.4% |
| 1 week | +0.1% | −3.8% | −0.2% |
| 1 month | +4.1% | +8.4% | +9.5% |
| 3 months | +1.5% | −1.8% | +18.2% |
| 6 months | −2.2% | −3.2% | +10.3% |
| Year to date | +8.4% | +16.1% | +19.3% |
| 1 year | +31.6% | +9.7% | +24.5% |
| 3 years, cumulative | +143.8% | +123.8% | +73.3% |
| 5 years, cumulative | +252.6% | +184.1% | +82.3% |
Technicals
4 measures| Measure | PH | TT | EMR |
|---|---|---|---|
| RSI 14 | 49.8 | 49.8 | 57.6 |
| From 52-week high | −12.2% | −9.1% | −2.6% |
| From 52-week low | +34.7% | +32.8% | +31.6% |
| Beta | 1.12 | 1.16 | 1.21 |
InsiderStreet reports findings from filings and market data. A comparison is not a recommendation to buy or sell either stock.Every figure is computed in code · data as of 2026-10-17